The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health